[1].NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma. Version 1.2025 审批编号:CN-146864有效期至:2025-01-06 本材料由阿斯利康提供,仅供医疗卫生专业人士参考 更多医疗资讯,...
我们应当积极借鉴国外研究的成果,探索我国CLL患者的特点,提高我国CLL的诊治水平。 1.Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer ...
2.《NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (Version 3.2019)》,2019 February 21. 临床指南邀请您参与小调研
[10] M.Dimopoulos, et al. Major responses in MYD88 wildtype (MYD88WT) Waldenström macroglobulinemia (WM) patients treated with bruton tyrosine kinase (BTK) inhibitor zanubrutinib. 2019 EHA oral presentation PF487. [11] NCCN Guidelines. Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma....
[11] NCCN Guidelines. Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma. V2.2023. [12] NCCN Guidelines. B-Cell Lymphomas.V2.2023. [13] NCCN Guidelines. Waldenström Macroglobulinemia / Lymphoplasmacytic Lymphoma.V1.2023. [14] CSCO 淋巴瘤诊疗指南 2023. ...
Poster: CLL-074: Insights From the informCLL Registry: Real-World Application of NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)doi:10.1016/S2152-2650(21)01386-0Nilanjan Ghosh...
For relapse of disease that occurs more than 3 y later, re-treat with first-line therapy; if relapse occurs after less than 2 y, see the NCCN guidelines for second-line therapies based on age and comorbidities [12] Locoregional radiation therapy is appropriate for patients with Ann Arbor ...
HOLLYWOOD, Florida — New and highly effective targeted therapies promise to change the landscape in the management of chronic lymphocytic leukemia (CLL), and those changes will soon be reflected in guidelines from the National Comprehensive Cancer Network (NCCN). Although watch and wait is still ...
Acalabrutinib (CALQUENCE®) is a NCCN Category 1 preferred treatment option for CLL in the NCCN Clinical Practice Guidelines for Oncology (NCCN Guidelines®)9 Acalabrutinib with or without obinutuzumab is recommended as a Category 1 preferred treatment option for patients with previously untreated...
虽然Pflug等 [ 11 ]及Rossi等 [ 12 ]等提出了其他的预后评分系统,但是由于如胸苷激酶(TK1)临床广泛开展的难度或未考虑临床特征如年龄、分期的局限性,故目前NCCN及iwCLL均推荐CLL-IPI评分系统作为新的预后积分体系。然而,由于东西方遗传背景的差异,比如我们既往的数据提示,中国CLL患者的发病中位年龄为62岁,早于...